Skip to main content

Table 3 Fasting metabolic abnormalities by ADT group (safety sample)

From: Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin–norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study

Metabolic measurement Incidence of potentially clinically relevant fasting metabolic abnormalities, n (%) Mean (SE) fasting metabolic parameters, mg/dL
Bupropion plus aripiprazole SSRI/SNRI plus aripiprazole Bupropion plus aripiprazole1 SSRI/SNRI plus aripiprazole2
    Baseline Change from baseline at Week 52 Baseline Change from baseline at Week 52
Glucose 3/36 (8.3) 35/201 (17.4) 95.0 (2.4) 1.4 (1.9) 94.4 (1.3) 2.7 (1.5)
Total cholesterol 9/36 (25.0) 70/202 (34.7) 209.6 (6.3) -0.9 (6.6) 214.2 (3.2) -0.9 (2.6)
LDL cholesterol 3/35 (8.6) 48/202 (23.8) 121.6 (5.3) 0.5 (5.7) 125.1 (2.9) -3.1 (2.5)
HDL cholesterol 1/36 (2.8) 6/202 (3.0) 55.0 (3.0) 0.3 (1.4) 56.4 (1.2) -0.5 (0.7)
Triglycerides       
Male 9/13 (69.2) 34/65 (52.3) 183.0 (36.6) 7.5 (13.7) 180.0 (13.9) 28.2 (19.9)
Female 15/23 (65.2) 100/137 (73.0) 157.5 (16.0) -25.3 (8.9) 156.9 (9.7) 8.5 (7.1)
  1. ADT, antidepressant treatment; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SNRI, serotonin–norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.
  2. Number of patients with both baseline and endpoint laboratory assessments: 1n = 32 (male, n = 11; female, n = 21); 2n = 181 (male, n = 58; female, n = 123) for all parameters except fasting glucose, where n = 179.